None

Justin Baldoni's lawyer has claimed "leaked" text exchanges about Blake Lively "lack critical context"Hyderabad: A deputy tehsildar (naib tehsildar) of Shankarapatnam mandal Siddipet district was caught red-handed by Telangana’s anti corruption bureau (ACB) for demanding a bribe of of Rs. 6000 for doing official work. The deputy tehsildar demanded the bribe money from the complainant to forward a file of Nala conversion of agriculture land measuring 2.25 guntas to Tahsildar. ACB officials recovered the bribe money from the possession of the accused government officer. The fingers of his right hand yielded positive in a chemical test. The deputy tehsildar was produced before the Special Judge for SPE & ACB cases in Karimnagar. Earlier in the day, ACB arrested another government officer in Bhadradri Kothagudem district for demanding a bribe of Rs 50,000 for performing official duties. The arrested official, identified as Merugu Rathnam, has been working as the deputy surveyor at Dammannapet Mandal in Kothagudem. He was caught taking the bribe money for conducting a land survey and submitting an official survey report at the property owned by the complainant’s sister. Citizens can report incidents of bribery by calling the hotline 1064.Global Launch of JETOUR T2 i-DM: Reshaping the Hybrid SUV Market

Israel launches new strikes on Lebanon as leaders draw closer to ceasefire with HezbollahZymeworks Inc. ( NYSE:ZYME – Get Free Report ) Director Ecor1 Capital, Llc bought 16,692 shares of the stock in a transaction on Thursday, December 26th. The stock was acquired at an average cost of $14.38 per share, for a total transaction of $240,030.96. Following the acquisition, the director now directly owns 14,720,931 shares in the company, valued at approximately $211,686,987.78. The trade was a 0.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website . Ecor1 Capital, Llc also recently made the following trade(s): Zymeworks Price Performance Shares of NYSE:ZYME opened at $14.50 on Friday. Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.70. The company’s 50-day moving average price is $14.25 and its two-hundred day moving average price is $12.00. The firm has a market cap of $998.73 million, a P/E ratio of -9.67 and a beta of 1.12. Analysts Set New Price Targets Several analysts have issued reports on the stock. Leerink Partners upgraded shares of Zymeworks from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $10.00 to $25.00 in a research report on Thursday, November 7th. Stifel Nicolaus boosted their price target on Zymeworks from $21.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, October 28th. Wells Fargo & Company upped their price target on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. Citigroup lifted their price objective on Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Finally, Leerink Partnrs upgraded Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.17. View Our Latest Stock Analysis on Zymeworks Institutional Trading of Zymeworks Institutional investors have recently bought and sold shares of the business. FMR LLC boosted its holdings in Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after buying an additional 1,525 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Zymeworks during the third quarter worth $47,000. Quest Partners LLC lifted its holdings in shares of Zymeworks by 8,049.6% in the second quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock valued at $78,000 after purchasing an additional 9,096 shares in the last quarter. nVerses Capital LLC acquired a new position in Zymeworks during the 3rd quarter worth approximately $79,000. Finally, MQS Management LLC bought a new position in shares of Zymeworks in the 2nd quarter valued at about $92,000. Institutional investors and hedge funds own 92.89% of the company’s stock. About Zymeworks ( Get Free Report ) Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. See Also Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter .None

Boise State edges SDSU men in Cayman Islands Classic semifinals

Uruguay's voters choose their next president in a close runoff with low stakes but much suspense‘Gladiator II’ review: Are you not moderately entertained?Goold's chat: If Cardinals trade closer Ryan Helsley, when's best time to maximize offer?

PSX hits peak with 80% growthPakistan's indigenously designed assessment system has dramatically reduced the clearance time of containers by 39% and curbed arm-twisting from importers by 83% in less than two weeks, reinforcing that real reforms do not need any foreign loan or advisory. After the implementation of the Faceless Customs Assessment (FCA) system, the average dwell time – the time a container takes at port – has reduced from 108 hours to 66 hours within two weeks. The significant reduction became possible after the Federal Board of Revenue (FBR) ended contact between the importer and appraiser and rolled out the automated faceless clearance system on December 15. The new system has been installed by bringing changes to the FBR's own WeBOC platform. These changes are aligned with provisions of the Customs General Order and other relevant legal provisions, in line with the modern trade facilitation standards. FBR Chairman Rashid Langrial has introduced the new system without taking any policy loan from foreign lenders. Nor did he hire any foreign advisory firm. The new system seeks to address the lingering systemic and individual issues by enabling remote, technology-driven customs assessments that minimise physical interactions through automated processes. The 66-hour clearance time is still far higher than the world average of less than half an hour and about two hours for a country like Pakistan. However, the time can be substantially reduced if the faceless assessment system, which is currently being implemented in Karachi only, is extended to other border areas and dry ports. FBR's data showed that there had also been an 86% reduction in the examination of containers – a tool that appraisers often used before December 15 for arm twisting. Any delay during examination increased the cost for importers in the shape of demurrage charges. It did not leave any option for them but to pay bribe to avoid additional port charges. The FBR chairman said that compared to December 15, the examination cases were slashed from 717 to just 98 – a reduction of 86%. Likewise, the number of cases called for documents went down from 3,346 in the pre-automation period to just 564 – a reduction of 83%. Langrial said that the high number of cases for calling documents reflected the arm twisting of importers. Despite rolling out the new system, there has not been any reduction in the filing of goods declarations and the payment of duties and taxes. From December 16 to 27, about 21,380 goods declarations were filed, which was 7% higher than the pre-automation fortnight. And the cases marked for assessment decreased 30% in an indication of lessening chances of kickbacks. The government received Rs116.4 billion in import taxes from December 16 to 27, up 14% compared to the previous fortnight. Improving efficiency, transparency and reducing the clearance time are critical to supporting economic growth and promoting ease of doing business. The FBR is of the view that anonymity in assessment helps reduce the physical interface between the trade and customs. It has installed real-time dashboards for tracking assessments and system performance. Alerts for delays or irregularities are generated. In the first phase, the consignments selected by the automated Risk Management System at the terminals of Karachi Port and Port Muhammad Bin Qasim are processed through the new system. Documents are allocated to the assessment units at the Collectorates of Appraisement East, West and Port Qasim. Goods declaration documents are assigned to the staff randomly in a group-less setting – one declaration at a time on a "first-in, first-out" (FIFO) basis – by the customs computerised system. Employees are not allowed to take their mobile phones inside the assessment hall aimed at minimising the chance of contact with the importer, Langrial said. The FBR will implement the second phase by June 2025. In phase-II, the new system will be extended to all Appraisement Collectorates of the country, any other dry ports and the land border stations working under the Enforcement & Export Collectorates for import consignments. Islamabad Dry port and Sialkot Dry Port will be brought under the new system by establishing units in Lahore, Peshawar and Quetta under the chief collectors of appraisement Punjab, North and Balochistan, respectively. These units will cover the goods declarations filed in the Appraisement Collectorates working under the respective jurisdictions of chief collectors appraisement. The assessment of declarations filed at any dry port and customs station not falling under the jurisdiction of a chief collector appraisement will also be marked at the CAU for faceless customs assessment. In the third phase, the FBR plans to roll out the new system at all airports and Export Collectorates. The assessment staff at airports and Export Collectorates will be made part of the pool at these assessment units for all import and export consignments. The eligibility criteria and licensing regime of customs clearing agents have also been revamped and a point-scoring system is being introduced to make them responsible for correct declarations. Under the point-scoring system, the customs agents who give true and honest declarations of description, value and origin will score more points and their profile will improve. On the contrary, the customs agents who fail to show improvements in declarations will lose points and eventually their licence may be cancelled. COMMENTS Comments are moderated and generally will be posted if they are on-topic and not abusive. For more information, please see our

Israel launches new strikes on Lebanon as leaders draw closer to ceasefire with Hezbollah

CHICAGO (AP) — Chicago Bulls guard Ayo Dosunmu has a strained right calf and will be reevaluated in 10 days. Dosunmu got hurt during Monday night’s 112-91 loss to Milwaukee. The Bulls provided an update on his injury on Saturday. Dosunmu, who turns 25 on Jan. 17, is averaging 12.6 points and 4.8 assists in his fourth NBA season. He has appeared in 30 games, including 17 starts. The Chicago native was selected by the Bulls in the second round of the 2021 draft. ___ AP NBA: https://apnews.com/hub/NBARobin Goodfellow's racing tips: Best bets for Tuesday, November 26

Galectin Therapeutics Inc. ( NASDAQ:GALT – Get Free Report ) CFO Jack W. Callicutt sold 40,000 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.89, for a total value of $35,600.00. Following the completion of the transaction, the chief financial officer now directly owns 7,614 shares in the company, valued at approximately $6,776.46. This trade represents a 84.01 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link . Galectin Therapeutics Stock Performance Shares of GALT stock opened at $1.15 on Friday. Galectin Therapeutics Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $4.27. The company has a 50 day moving average price of $2.34 and a 200 day moving average price of $2.43. The stock has a market capitalization of $72.18 million, a P/E ratio of -1.58 and a beta of 0.69. Institutional Inflows and Outflows Several institutional investors and hedge funds have recently bought and sold shares of the stock. Commonwealth Equity Services LLC lifted its position in shares of Galectin Therapeutics by 317.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 483,351 shares of the company’s stock worth $1,092,000 after purchasing an additional 367,610 shares during the last quarter. Soltis Investment Advisors LLC acquired a new stake in shares of Galectin Therapeutics during the 3rd quarter worth about $387,000. Sanctuary Advisors LLC purchased a new stake in Galectin Therapeutics during the second quarter worth approximately $227,000. Bank of New York Mellon Corp acquired a new position in Galectin Therapeutics in the second quarter valued at approximately $146,000. Finally, Kovitz Investment Group Partners LLC purchased a new position in Galectin Therapeutics in the third quarter valued at approximately $117,000. 11.68% of the stock is owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth Get Our Latest Stock Report on GALT Galectin Therapeutics Company Profile ( Get Free Report ) Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Featured Stories Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .One of the few things left that the Las Vegas Raiders fan base had to look forward to, outside of the No. 1 pick, which was ruined, was a potential reunion between Derek Carr and the New Orleans Saints. That rematch, or revenge game, whatever you want to call it, was something every fan wanted to see. And this fan base has been pretty split on Carr, whether they wanted to keep him or get rid of him. But everyone wanted to see that game. But, of course, we soon figured out that the Saints will not be playing Carr, as he has been injured for some time now, and while he just got healthy, he still isn't ready for game action yet. The Saints will instead be playing Spencer Rattler as their starting QB. And, you'd think some of the players would be excited for this game against Carr, too, but then you think about it, and, not many of his former teammates are even on the team. When Antonio Pierce was asked about that, he kept it real. Antonio Pierce comments on Raiders potentially facing Derek Carr this Sunday: "It's not the same team here. To be honest, it hasn't been talked about." #RaiderNation | #Saints pic.twitter.com/d7EjSnP65X "It's not the same team here. To be honest, it hasn't been talked about," Pierce said to the media earlier this week. And, he's right -- it's been two years and there has been a lot of turnover. No more Josh Jacobs, no more Hunter Renfrow, Darren Waller, Foster Moreau, and you can keep going honestly. I'll give you a beat of coach speak here and say, they are just worried about getting a win, even though they don't need need to win it. The Raiders should actually be trying to lose this game, and if they do, at least it's not against Carr. After this game, the Raiders will finish out their season against the Los Angeles Chargers. This article first appeared on A to Z Sports and was syndicated with permission.